Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD) had its price objective trimmed by Cantor Fitzgerald from $3.00 to $2.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other brokerages have also commented on LUCD. Ascendiant Capital Markets dropped their price objective on Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a report on Tuesday, September 10th. Canaccord Genuity Group raised shares of Lucid Diagnostics to a “strong-buy” rating in a research note on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a research report on Thursday. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research report on Thursday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Lucid Diagnostics has a consensus rating of “Buy” and an average price target of $3.69.

Lucid Diagnostics Stock Down 2.3 %

Shares of NASDAQ:LUCD traded down $0.02 during trading on Friday, reaching $0.99. 428,162 shares of the company’s stock traded hands, compared to its average volume of 195,200. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.58. The company has a 50-day simple moving average of $0.87 and a 200-day simple moving average of $0.85. The firm has a market cap of $53.28 million, a PE ratio of -0.87 and a beta of 1.41.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC grew its holdings in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,671 shares of the company’s stock after buying an additional 13,835 shares during the period. Virtu Financial LLC owned 0.07% of Lucid Diagnostics worth $28,000 as of its most recent filing with the Securities & Exchange Commission. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.